Real-world experience with secukinumab in the entire axial spondyloarthritis spectrum.

Autor:	Sivera F; Rheumatology Department, Hospital General Universitario de Elda, Alicante, Spain.; Departament of Clinical Medicine, Universidad Miguel Hernandez, Elche, Spain., Núñez-Monje V; Rheumatology Department, Hospital Universitario Dr Peset, Valencia, Spain., Campos-Fernández C; Rheumatology Department, Hospital General Universitario, Valencia, Spain., Balaguer-Trull I; Rheumatology Department, Hospital General Universitario, Valencia, Spain., Robustillo-Villarino M; Reumatology Unit, Internal Medicine Department, Hospital Universitario de la Plana, Villarreal, Spain., Aguilar-Zamora M; Rheumatology Department, Hospital de Sagunto, Sagunto, Spain., Garijo-Bufort M; Rheumatology Department, Hospital de Sagunto, Sagunto, Spain., López-Gómez JM; Rheumatology Department, Hospital General Universitario de Elda, Alicante, Spain., Peña-González C; Rheumatology Department, Hospital Francesc de Borja, Gandía, Spain., de la Morena I; Rheumatology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain., Bedoya-Sanchís D; Rheumatology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain., Yankova-Komsalova L; Rheumatology Department, Hospital Marina Salud, Denia, Alicante, Spain., Conesa-Mateos A; Rheumatology Department, Hospital General Universitari de Castelló, Castellón, Spain., Martínez-Cristóbal A; Rheumatology Department, Hospital Universitario de La Ribera, Alzira, Spain., Navarro-Blasco FJ; Rheumatology Department, Hospital Universitario de Elche, Elche, Alicante, Spain., Senabre-Gallego JM; Rheumatology Department, Hospital Marina Baixa, La Vila Joiosa, Spain., Alegre-Sancho JJ; Rheumatology Department, Hospital Universitario Dr Peset, Valencia, Spain.
Jazyk:	angličtina
Zdroj:	Frontiers in medicine [Front Med (Lausanne)] 2023 May 11; Vol. 10, pp. 1156557. Date of Electronic Publication: 2023 May 11 (Print Publication: 2023).
DOI:	10.3389/fmed.2023.1156557
Abstrakt:	Background: Secukinumab is a biologic disease-modifying antirheumatic drug (bDMARD) that has demonstrated efficacy in the treatment of axial spondyloarthritis (axSpA, i.e., ankylosing spondylitis and non-radiographic axSpA) across various clinical trials. However, data of secukinumab in clinical practice is still limited. Here, we aimed to provide real-world data on secukinumab use, effectiveness, and persistence in axSpA. Patients and Methods: Retrospective, multicenter study of patients with a diagnosis of axSpA treated with secukinumab at 12 centers up to June 2021 in the Valencian Community (Spain). Information was gathered on BASDAI measurement, pain, patient and physician global assessment (ptGA, phGA) using a 100-mm visual analog scale (VAS), persistence and other secondary variables by treatment line (first, second, and ≥ third) for up to 24 months. Results: 221 patients were included (69% men; mean age [standard deviation, SD]: 46.7 [12.1] years old). Secukinumab was used as a first-line bDMARD in 38% of patients, as a second-line in 34% and as a ≥ hird-line in 28%. The percentage of patients achieving low disease activity (BASDAI<4) increased from 9% at baseline to 48% at month 6 and was maintained (49%) up to month 24. The greatest improvement in BASDAI was observed in naïve patients (month 6: -2.6; month 24: -3.7), followed by second-line (month 6: -1.9; month 24: -3.1) and ≥ third-line (month 6: -1.3; month 24: -2.3) patients. Reductions in mean pain VAS (-23.3; -31.9), ptGA (-25.1; -31.9) and phGA (-25.1; -31) were also observed at 6 and 24 months. Secukinumab showed an overall 12-months persistence rate of 70% (95% confidence interval [CI]: 63-77%) and a 24-months persistence rate of 58% (95% CI, 51-66%). Patients receiving first-line secukinumab had the highest 24-months persistence rate ( p  = 0.05). Conclusion: Secukinumab improved disease activity in axSpA patients, especially in naive, and second-line patients, which was accompanied by high persistence rates up to 24 months. Competing Interests: FS received honoraria as a consultant from AbbVie, Pfizer, Astra Zeneca. Grant/Research support from AbbVie, Novartis, Eli Lilly, Roche, BMS. JMSG reports personal fees and non-financial support from Abbvie, non-financial support from BMS, personal fees from Celgene, personal fees from Janssen, non-financial support from Lilly, non-financial support from MSD, personal fees from Novartis, non-financial support from Pfizer, non-financial support from Roche, non-financial support from UCB, outside the submitted work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Sivera, Núñez-Monje, Campos-Fernández, Balaguer-Trull, Robustillo-Villarino, Aguilar-Zamora, Garijo-Bufort, López-Gómez, Peña-González, de la Morena, Bedoya-Sanchís, Yankova-Komsalova, Conesa-Mateos, Martínez-Cristóbal, Navarro-Blasco, Senabre-Gallego and Alegre-Sancho.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu